5:46 PM
Nov 07, 2008
 |  BC Extra  |  Company News

Amgen provides business update

Amgen (NASDAQ:AMGN) said in a business update on Friday that it expects two products to achieve blockbuster status in three indications over the next five years: hyperparathyroidism drug Sensipar cinacalcet; and denosumab for osteoporosis and cancer-related indications. The company said it expects to complete its BLA data package for the...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >